Endpoints News Q3 2025 Update – Part 1 – October 13, 2025

Is the worst over? Biopharma dealmaking shows an uptick in third quarter

Biopharma dealmaking and investment activity rebounded in Q3 2025, signaling potential recovery for the sector after a prolonged downturn, as highlighted in a two-part Endpoints special featuring analysis by DealForma CEO Chris Dokomajilar. Read it here

DealForma Research

Explore More
Biopharma Therapeutics and Platform IPOs Follow-on and PIPE Issuances - Q3 2025 Review

Biopharma Therapeutics and Platform IPOs Follow-on and PIPE Issuances – Q3 2025 Review

Biopharma Therapeutics and Platform Venture Funding - Q3 2025 Review

Biopharma Therapeutics and Platform Venture Funding – Q3 2025 Review

Biopharma Therapeutics and Platforms M&A – Q3 2025 Review

Biopharma Therapeutics and Platform M&A – Q3 2025 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive